D
espite increasing interest in additional arterial conduits during coronary artery bypass graft (CABG) surgery, 1 the search for the optimum additional arterial conduit to supplement the left internal thoracic artery continues. The radial artery (RA) has been shown to provide better patency rates than saphenous vein grafts (SVGs), 2, 3 but whether this translates into superior clinical outcomes remains unclear. A few randomized controlled trials investigating the effect of RA grafts on clinical outcomes were underpowered to detect differences in clinical outcomes. [4] [5] [6] On the other hand, observational studies that have focused only on survival have reported discordant results. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] The ART (Arterial Revascularization Trial) was designed to compare survival after bilateral internal thoracic artery (BITA) versus single left internal thoracic artery (SITA). The interim midterm results (5 years) demonstrated no difference between the groups. 1 A large proportion of the ART patients (≈20%) received the RA as a second conduit to supplement an SITA graft or as a third conduit to supplement BITA grafts, making the ART the largest series of RA grafting in the context of a randomized trial involving SITA or BITA.
We aimed to investigate the associations between the use of an RA graft to supplement either SITA or BITA grafts and clinical outcomes by performing a post hoc analysis of the ART.
METHODS
The present study is a post hoc analysis of 5-year outcomes of the ART. This research adheres to the principles set forth in the Declaration of Helsinki (http://www.wma.net/ en/30publications/10policies/b3/index.html). In the ART, the use of the RA was based on surgeon's discretion. For the purpose of the present analysis, patients enrolled in the ART (n=3102) were classified on the basis of conduits actually received (astreated principle). The present analyses compared the strategy using the RA with or without additional SVG (RA group) versus SVG only (SVG group) to supplement SITA or BITA grafts.
The following patients were excluded from the present analyses: those in whom neither SVG nor RA was used (n=328), patients receiving SVG but neither SITA nor BITA graft (n=30), and patients receiving an RA graft but neither SITA nor BITA used (n=7).
Trial Design
The ART was approved by the institutional review board of all participating centers, and informed consent was obtained from each participant. The protocol for the ART has been published. 17 Briefly, the ART is a 2-arm, randomized multicenter trial conducted in 28 hospitals in 7 countries, with patients being randomized equally to SITA or BITA grafts. Eligible patients were those with multivessel coronary artery disease undergoing CABG, including urgent patients, with grafting recommended in case of target stenosis ≥75%. Only emergency patients (refractory myocardial ischemia/cardiogenic shock) and those requiring single grafts or redo CABG were excluded.
Follow-Up
Questionnaires were sent to study participants by post at 6 months and every year after surgery. No clinic visits were planned apart from the routine clinical 6-week postoperative visit. Participants were sent stamped, addressed envelopes to improve the return rates of postal questionnaires. Study coordinators contacted participants by telephone to alert them of the arrival of the questionnaire and to ask them about medications, adverse events, and health services resource use.
Study Outcomes
The primary outcome for this analysis was the composite of major adverse cardiac events (MACEs) at 5 years, including cardiovascular death, myocardial infarction (MI), and repeat revascularization. The associations between the use of an RA graft and MACE individual components and overall mortality were also investigated.
Hospital outcomes analyzed were hospital mortality, return to the operating room, postoperative intra-aortic balloon pump, renal replacement therapy, sternal wound infection, MI, cerebrovascular accident, repeat revascularization, and postoperative atrial fibrillation. Adverse events were adjudicated by members of the Clinical Event Review Committee who were blinded to the surgical procedure.
Statistical Analysis
For baseline characteristics, variables are summarized as mean and SD for continuous variables and as percentage for categorical variables. Multiple imputation (m=3) was used to address missing data. The Rubin 18 method was used to combine
Clinical Perspective
What Is New?
• The use of a radial artery graft has been associated with superior angiographic patency rates compared with saphenous vein grafts, but the clinical impact of using the radial artery remains unclear.
• We found that the radial artery used to supplement either single or bilateral internal thoracic artery grafts instead of saphenous vein grafts only was associated with a significantly lower risk for major adverse cardiac events with a significantly lower rate of reintervention and marginally lower risk for cardiovascular death and subsequent myocardial infarction.
What Are the Clinical Implications?
• The radial artery graft is simple to perform because its caliber and handling properties are similar to those of vein grafts, and in view of its superior patency over saphenous vein grafts, it is an ideal conduit to achieve multiple arterial grafting and may improve patient outcomes.
results from each of m imputed data sets (Amelia R package). Because of a lack of randomization with regard to receiving RA, a propensity score was generated for each patient from a multivariable logistic regression model based on pretreatment covariables as independent variables with RA versus SVG as a binary dependent variable. 19 Covariables included in the propensity score model were age, female sex, body mass index, systolic and diastolic blood pressures at admission, creatinine, New York Heart Association functional class, unstable angina, treated hypertension, treated hyperlipidemia, diabetes mellitus, smoking, chronic obstructive pulmonary disease, peripheral vascular disease, transient ischemic attack, cerebrovascular accident, MI, percutaneous coronary intervention, atrial fibrillation, left ventricular ejection fraction, dual antiplatelet therapy, off-pump surgery, BITA, left main stem disease, left anterior descending artery disease, circumflex artery disease, diagonal branch disease, and right coronary artery disease. Pairs of patients were derived with greedy 1:1 matching with a caliper of width of 0.2 SD of the logit of the propensity score (nonrandom R package). The quality of the match was assessed by comparing selected pretreatment variables in propensity score-matched patients using the standardized mean difference, for which an absolute standardized difference of >10% is suggested to represent meaningful covariable imbalance. The McNemar test and paired t test were used to assess the statistical significance of the risk difference in short-term outcomes in the matched sample. 19 A Cox regression model, stratified on the matched pairs, 19 was used to estimate the associations between treatment and the primary outcome and overall mortality. This approach accounts for the withinpair homogeneity by allowing the baseline hazard function to vary across matched sets (survival R package). Competing-risk analysis (prodlim and riskRegression R packages) was used to estimate the associations between treatment and the primary end point individual components. As sensitivity analysis, the associations between the use of an RA graft and outcomes were tested in a mixed-effect Cox model to account for clustering effect resulting from individual surgeons and centers 20 (http://CRAN.R-project.org/package=coxme). The association between use of an RA graft and outcomes was also adjusted for medication at discharge, including aspirin, clopidogrel, β-blockers, calcium channel antagonists (CCAs), statins, and angiotensin-converting enzyme inhibitors and angiotensin receptors blockers. Finally, possible modifiers of associations tested with interaction analyses were age <70 and ≥70 years, female versus male sex, diabetes mellitus versus no diabetes mellitus, reduced versus preserved left ventricular ejection fraction, SITA versus BITA graft, and off-versus on-pump surgery.
All P values were 2 sided, with P<0.05 considered to indicate statistical significance. All statistical analyses were performed with R Statistical Software (version 3.2.3; R Foundation for Statistical Computing, Vienna, Austria).
RESULTS

Study Sample
The final population included 2737 patients who received an RA graft (RA group; n=632) or SVG only (SVG group; n=2105). Among those who received an RA graft, SITA graft was used in 359 patients (57%) and BITA graft was used in 273 patients (43%). In the RA group, 397 patients (63%) underwent total arterial revascularization, whereas the remaining 235 (37%) received at least 1 additional SVG. In the SVG group, 1330 patients (63%) had SITA graft and the remaining 775 (37%) had BITA graft.
Graft Configuration and Target Details
Graft configurations and target characteristics in the RA and SVG groups are summarized in Table 1 . Overall, the quality (including size and need for endarterectomy) of targets grafted with the RA was not superior to that of targets grafted with SVG in the SVG group. Table I in the online-only Data Supplement summarizes graft configuration and target details in subjects receiving an RA graft to supplement SITA and BITA grafts. When the RA was used to supplement an SITA graft, it was preferentially used to graft the circumflex artery (65%), followed by the right coronary artery (22%). When the RA was used to supplement BITA grafts, it was preferentially used to graft the right coronary artery (64%), followed by the circumflex artery (25%).
RA Use Variation Across Surgeons and Centers
The present post hoc analysis included a total of 157 participating surgeons and 28 cardiac centers. The use of the RA over SVG significantly varied only across surgeons ( Figure 
Propensity Score Matching
Before matching, the RA and SVG groups showed significant differences in terms of preoperative nitrate administration, age, functional New York Heart Association class, rate of BITA graft use, body mass index, diabetes mellitus, and preoperative left ventricular ejection fraction. Patients receiving the RA were 2 years younger and more likely to have insulin-treated diabetes mellitus and decreased left ventricular ejection fraction. After propensity score matching, the 2 groups were comparable for all pretreatment characteristics (Table 2 and Figure 1 ).
Hospital Outcomes
Hospital outcomes are reported in Table 3 . Mortality rates and postoperative complications were comparable between the 2 groups.
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Outcomes at 5 Years
The 5-year outcomes are reported in 
Postoperative Medications
Medications prescribed at discharge are reported in Table II Figure 3 ).
Modifiers of the Associations Between RA Graft Use and Outcomes
None of possible modifiers of association investigated was found to influence the associations between RA graft use and MACEs compared with SVG only (Figure 4) . Subgroup analysis showed that the association between the RA and lower risk of MACEs was present for both SITA and BITA grafts (interaction P=0.62; Table III 
Angiographic Follow-Up
Angiographic follow-up was performed only in symptomatic patients; therefore, patency rates of different conduits could not be analyzed. For those who underwent repeat revascularization, clinical presentation and revascularization strategy adopted were not available in all cases. In the RA group, graft failure and native coronary disease progression were documented in 4 and 21 cases, respectively, among 27 cases of repeat revascularization. In the SVG group, graft failure and native coronary disease progression were documented in 54 and 90 cases, respectively, among 152 cases of repeat revascularization. All failed grafts were reported to be SVG. In the RA group, need for repeat CABG and repeat percutaneous coronary intervention was documented in 2 and 23 cases, respectively. In the SVG group, need for repeat CABG and repeat percutaneous coronary intervention was documented in 6 and 113 cases, respectively.
DISCUSSION
The main finding of the present analysis is that an RA graft (with or without additional vein graft) used to supplement either SITA and BITA grafts, instead of SVG only, was associated with significantly lower risk for major adverse cardiac events with a significantly lower rate of reintervention and marginally lower risk for cardiovascular death and subsequent MI, despite the fact that the quality of RA targets was not superior to that of SVG targets. On the other hand, use of an RA graft did not increase operative mortality or complications.
Although several randomized trials have shown that use of an RA graft is associated with superior 5-year patency rates compared with SVGs, 3, 4 whether this translates into better clinical outcomes remains uncertain. In fact, randomized controlled trials conducted to date are limited by small sample sizes, and the results are incon- 21 757 patients were randomly assigned to receive either SITA and RA grafts (n=366) or SITA and SVGs grafts (n=367). There was no significant difference between the 2 groups at 1 year in terms of death, MI, stroke, and repeat coronary revascularization. However, outcomes beyond 1 year are not available.
On the other hand, several retrospective studies that investigated the associations between the use of RA as an additional arterial conduit instead of SVG and outcomes reported discordant results for survival. Schwann Long-term survival in the BITA+RA groups was comparable to that in the BITA+SVG groups (P=0.25). Mohammadi and associates 14 16 and the 2 groups showed comparable 15-year survival rates (log-rank P=0.54).
The present post hoc ART analyses support the hypothesis that an additional RA may reduce midterm major adverse cardiac events when used to supplement either SITA or BITA grafts compared with SVG only. The better clinical outcomes observed in patients receiving an RA graft can be attributed to its superior patency rate compared with SVG. 2, 3, 22 An interim analysis of the ART 1 has shown that BITA grafts did not improve 5-year outcomes compared with an SITA strategy. However, the primary end point of the ART is 10-year survival, and those data will be needed to draw any conclusions on whether there is any potential benefit of BITA grafts over the longer term. Previous studies have supported the hypothesis that the beneficial effect from BITA on clinical outcomes may be delayed by as much as 7 to 10 years. 23 On the other hand, the RA graft is simple to perform because its caliber and handling properties are similar to those of vein grafts. The superior patency rate of the RA over SVG at 5 years has been demonstrated by several randomized controlled trials, 2 and the use of an RA graft has been reported to exhibit maximal benefit between 0.5 and 5 years. 7 The main limitations of the present analyses are the nonrandomized comparison and the low number of outcome events. Propensity score modeling included several variables, but we cannot exclude a residual selection bias based on a unmeasured or unmeasurable characteristics.
CONCLUSIONS
The present post hoc analysis of the ART showed that the use of an additional RA graft to supplement both SITA and BITA grafts was associated with a lower risk for MACEs at 5 years. From these results, it seems reasonable to consider the use of an RA graft a valid option for multiple arterial grafting.
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